B. Riley raised the firm’s price target on OptimizeRx (OPRX) to $18 from $13 and keeps a Buy rating on the shares. OptimizeRx reported “strong” Q1 results, beating consensus estimates on sales and adjusted EBITDA, while raising fiscal 2025 guidance for sales and adjusted EBITDA, the analyst tells investors in a research note. The firm views the potential elimination of direct-to-consumer pharmaceutical TV advertising to be a tailwind, driving more spend toward OptimizeRx’s targeted marketing approach, and remains confident in the company’s future outlook.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target raised to $22 from $16 at Roth Capital
- OptimizeRx price target raised to $12.50 from $8 at Stifel
- OptimizeRx price target raised to $14 from $11 at Citizens JMP
- OptimizeRx Reports Strong Q1 2025 Financial Growth
- OptimizeRx: Strong Financial Performance and Strategic Growth Positioning for Potential Acquisition
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue